Get the Stockscreener App
65.35
1.41%
0.91
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $65.35, with a volume of 8.99M.
It is up +1.41% in the last 24 hours and up +3.40% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$64.44
Open:
$63.93
24h Volume:
8.99M
Relative Volume:
1.70
Market Cap:
$202.63B
Revenue:
$51.21B
Net Income/Loss:
$6.50B
P/E Ratio:
33.01
EPS:
1.98
Net Cash Flow:
$6.76B
1W Performance:
-1.85%
1M Performance:
+3.40%
6M Performance:
-16.82%
1Y Performance:
-0.65%
1-Day Range:
$63.75
$65.47
1-Week Range:
$63.75
$67.47
52-Week Range:
$60.47
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
65.35 | 202.63B | 51.21B | 6.50B | 6.76B | 2.085 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Why Astrazeneca (AZN) Outpaced the Stock Market Today - Yahoo Finance
Analysts are saying the AstraZeneca share price looks cheap despite China turmoil - MSN
AstraZeneca takes advantage of Tanium’s integrations with Microsoft & ServiceNow - Tech Monitor
Beijing Woos AstraZeneca for Investment While Probe Continues - BNN Bloomberg
AstraZeneca PLC ADR falls Thursday, underperforms market - MarketWatch
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman - GlobeNewswire
AstraZeneca outperforms market despite losses on the day - MarketWatch
AstraZeneca PLC Announcement: If You Have Suffered Losses - GlobeNewswire
AstraZeneca strengthens global operations despite China challenges - IG
AstraZeneca PLC ADR underperforms Wednesday when compared to competitors - MarketWatch
AstraZeneca falls Wednesday, underperforms market - MarketWatch
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexif - Quantisnow
AstraZeneca insiders expect sales dip in China after arrest of local boss - Financial Times
Rosen Law Firm Encourages AstraZeneca PLC Investors to Inquire About Securities Class Action InvestigationAZN - Morningstar
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
Is AstraZeneca PLC (AZN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? - Insider Monkey
AstraZeneca is expanding in Cambridge as it plans to grow Mass. presence - The Business Journals
Rosen Law Firm Encourages AstraZeneca PLC Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – AZN - Business Wire
AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch
AstraZeneca rises Monday, outperforms market - MarketWatch
AstraZeneca's SWOT analysis: oncology giant's stock poised for growth - Investing.com
AstraZeneca announces board refresh with new directors - Investing.com
AstraZeneca PLC (NASDAQ:AZN) Short Interest Down 8.3% in November - MarketBeat
AstraZeneca goes cheap – should you buy? - MoneyWeek
AstraZeneca: two appointments to the Board of Directors - Marketscreener.com
AstraZeneca Strengthens Board with New Non-Executive Director Appointments - TipRanks
AstrazenecaPotential Approval For Soliris Would Mark First An… - Marketscreener.com
AstraZeneca names new non-executive directors - Investing.com
AstraZeneca Strengthens Leadership with New Appointments - Devdiscourse
3 Unstoppable Stocks to Buy Right Now - The Motley Fool
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by State Street Corp - MarketBeat
Peapack Gladstone Financial Corp Grows Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Verition Fund Management LLC Has $338,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca Says Andexxa Will Not Convert To Full Approval, Quietly Reveals Complete Response - Citeline News & Insights
AstraZeneca PLC ADR underperforms Friday when compared to competitors - MarketWatch
AstraZeneca falls Friday, underperforms market - MarketWatch
AstraZeneca PLC (NASDAQ:AZN) Stock Position Raised by Franklin Resources Inc. - MarketBeat
Wilmington Savings Fund Society FSB Buys New Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Vestcor Inc Has $1.02 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Hutchmed to get Takeda milestone payment - Marketscreener.com
AstraZeneca Partners with Tracer Bio for Revolutionary Cancer Monitoring Technology - StockTitan
AstraZeneca’s Anna Berg Asberg on Scaling Generative AI at AI Summit New York - IoT World Today
AstraZeneca rises Thursday, outperforms market - MarketWatch
Virtu Financial LLC Purchases New Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca: Lynparza shows promise in breast cancer - Marketscreener.com
Pitavastatin Market Key Players AnalysisPfizer Inc., AstraZeneca PLC, Novartis International AG, GlaxoSmithKline plc. - openPR
AstraZeneca Sees Bright Future For Registry-Based Randomized Clinical Trials - News & Insights
AstraZeneca PLC ADR rises Wednesday, still underperforms market - MarketWatch
AstraZeneca, Merck report positive long-term data for Lynparza - MSN
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients - Yahoo Finance
AstraZeneca, Merck report positive long-term data for Lynparza (NASDAQ:AZN) - Seeking Alpha
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):